Skip to main content
. 2019 May 29;11:4893–4904. doi: 10.2147/CMAR.S164935

Table 2.

Efficacy of nivolumab and ipilimumab as first-line treatment in advanced NSCLC patients with high TMB

Study N RR (%) DoR (mo.) PFS (mo) OS (mo.)
CheckMate 01251 24 51 Not reported 17.1 Not reported
CheckMate 56814 49 44 Not reported 7.2 Not reported
CheckMate 2279 139 45.3 Not reached. 1-year DoR: 68% 7.2 23.3
CheckMate 817*54 73 54 Not reported 10.9 Not reported

Abbreviations: DoR, duration of response. PFS, progression-free survival. OS, overall survival; mo., months; TMB, tumor mutation burden.*Cohort A.